CSF-1 在卵巢上皮性癌进展中的作用。
Role of CSF-1 in progression of epithelial ovarian cancer.
机构信息
Women's Cancers, Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA.
出版信息
Future Oncol. 2009 Nov;5(9):1429-40. doi: 10.2217/fon.09.103.
Abstract
Despite the dismal outcome seen in the majority of epithelial ovarian cancer patients, there is ongoing progress in understanding the disease at a molecular level. Elucidation of pathways underlying disease progression and metastasis of ovarian cancer is key to development of targeted therapeutics. It is only in this way that therapeutic potential can be translated to reality. Here, we describe the evidence to date for the role of CSF-1/c-fms signaling in ovarian cancer invasiveness and metastasis, including the recent understanding of how CSF-1/c-fms expression is regulated with identification of significant post-transcriptional regulators.
摘要
尽管大多数上皮性卵巢癌患者的预后不佳，但在分子水平上对该疾病的认识仍在不断取得进展。阐明卵巢癌进展和转移的途径是开发靶向治疗的关键。只有这样，治疗潜力才能转化为现实。在这里，我们描述了 CSF-1/c-fms 信号在卵巢癌侵袭和转移中的作用的现有证据，包括最近对 CSF-1/c-fms 表达如何受到调控的理解，以及鉴定出重要的转录后调控因子。
相似文献
1
Role of CSF-1 in progression of epithelial ovarian cancer.CSF-1 在卵巢上皮性癌进展中的作用。
Future Oncol. 2009 Nov;5(9):1429-40. doi: 10.2217/fon.09.103.
2
Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients.造血细胞因子作为妇科恶性肿瘤的肿瘤标志物：上皮性卵巢癌患者的多变量分析
Growth Factors. 2012 Dec;30(6):357-66. doi: 10.3109/08977194.2012.724407. Epub 2012 Sep 18.
3
Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.巨噬细胞集落刺激因子通过尿激酶介导卵巢癌细胞的侵袭。
Cancer Res. 1995 Apr 1;55(7):1578-85.
4
Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.粒细胞集落刺激因子受体通过 Janus 激酶 2/信号转导子和转录激活子 3 在卵巢癌中的信号转导。
Br J Cancer. 2014 Jan 7;110(1):133-45. doi: 10.1038/bjc.2013.673. Epub 2013 Nov 12.
5
Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.采用 iTRAQ 技术在大鼠模型中发现与浆液性卵巢癌发生和进展相关的血清生物标志物。
Eur J Obstet Gynecol Reprod Biol. 2012 Nov;165(1):96-103. doi: 10.1016/j.ejogrb.2012.06.031. Epub 2012 Jul 18.
6
OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.OVX1、巨噬细胞集落刺激因子和CA-125-II作为上皮性卵巢癌的肿瘤标志物：一项批判性评估。
Cancer. 2001 Dec 1;92(11):2837-44. doi: 10.1002/1097-0142(20011201)92:11<2837::aid-cncr10093>3.0.co;2-5.
7
Nerve growth factor stimulates cellular proliferation of human epithelial ovarian cancer.神经生长因子刺激人卵巢上皮癌细胞的增殖。
Horm Metab Res. 2012 Sep;44(9):656-61. doi: 10.1055/s-0032-1304617. Epub 2012 Mar 12.
8
Ovarian enzymatically active stromal cells can be a promoter of ovarian surface epithelial tumor.卵巢有酶活性的基质细胞可能是卵巢表面上皮肿瘤的促进因素。
Med Hypotheses. 2011 Sep;77(3):356-8. doi: 10.1016/j.mehy.2011.05.014. Epub 2011 Jun 8.
9
Messenger RNA decay of macrophage colony-stimulating factor in human ovarian carcinomas in vitro.人卵巢癌中巨噬细胞集落刺激因子信使核糖核酸的体外衰变
J Soc Gynecol Investig. 1994 Oct-Dec;1(4):310-6. doi: 10.1177/107155769400100411.
10
Gonadotropins and ovarian cancer.促性腺激素与卵巢癌
Endocr Rev. 2007 Jun;28(4):440-61. doi: 10.1210/er.2006-0036. Epub 2007 Apr 26.
引用本文的文献
1
Effect of MisMatch repair deficiency on metastasis occurrence in a syngeneic mouse model.错配修复缺陷对同基因小鼠模型中转移发生的影响。
Neoplasia. 2025 Apr;62:101145. doi: 10.1016/j.neo.2025.101145. Epub 2025 Feb 21.
2
Single-cell transcriptomics predict novel potential regulators of acute epithelial restitution in the ischemia-injured intestine.单细胞转录组学预测缺血性损伤肠道中急性上皮修复的新型潜在调节因子。
Am J Physiol Gastrointest Liver Physiol. 2025 Mar 1;328(3):G182-G196. doi: 10.1152/ajpgi.00194.2024. Epub 2025 Jan 24.
3
miR-449, identified through antiandrogen exposure, mitigates functional biomarkers associated with ovarian cancer risk.通过抗雄激素暴露鉴定出的miR-449可减轻与卵巢癌风险相关的功能生物标志物。
Sci Rep. 2024 Dec 2;14(1):29937. doi: 10.1038/s41598-024-80173-z.
4
Leptin signalling regulates transcriptional differences in granulosa cells from genetically obese mice but not the activation of NLRP3 inflammasome.瘦素信号调节肥胖基因小鼠颗粒细胞中的转录差异，但不调节 NLRP3 炎性小体的激活。
Sci Rep. 2024 Apr 5;14(1):8070. doi: 10.1038/s41598-024-58181-w.
5
Antiandrogen Flutamide-Induced Restoration of miR-449 Expression Mitigates Functional Biomarkers Associated with Ovarian Cancer Risk.抗雄激素氟他胺诱导的miR-449表达恢复减轻了与卵巢癌风险相关的功能生物标志物。
medRxiv. 2024 Feb 29:2024.02.26.24303311. doi: 10.1101/2024.02.26.24303311.
6
Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer.集落刺激因子-1受体抑制联合紫杉醇在卵巢癌治疗中发挥有效的抗肿瘤作用。
Genes Dis. 2023 Jun 22;11(3):100989. doi: 10.1016/j.gendis.2023.04.023. eCollection 2024 May.
7
Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies.卵巢癌中的巨噬细胞及其与单克隆抗体疗法的相互作用。
Clin Exp Immunol. 2022 Jul 22;209(1):4-21. doi: 10.1093/cei/uxab020.
8
Inflammation and tumor progression: signaling pathways and targeted intervention.炎症与肿瘤进展：信号通路与靶向干预。
Signal Transduct Target Ther. 2021 Jul 12;6(1):263. doi: 10.1038/s41392-021-00658-5.
9
CSF-1 Overexpression Predicts Poor Prognosis in Upper Tract Urothelial Carcinomas.CSF-1 过表达预示上尿路上皮癌预后不良。
Dis Markers. 2019 Aug 21;2019:2724948. doi: 10.1155/2019/2724948. eCollection 2019.
10
Circulating miRNA Profiling of Women at High Risk for Ovarian Cancer.卵巢癌高危女性的循环微小RNA分析
Transl Oncol. 2019 May;12(5):714-725. doi: 10.1016/j.tranon.2019.01.006. Epub 2019 Mar 9.
本文引用的文献
1
Biomarker targets and novel therapeutics.生物标志物靶点与新型疗法。
Cancer Treat Res. 2009;149:85-105. doi: 10.1007/978-0-387-98094-2_4.
2
HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer.HuR在细胞核中的表达与卵巢癌的高组织学分级及无病生存期短相关。
Aust N Z J Obstet Gynaecol. 2009 Feb;49(1):93-8. doi: 10.1111/j.1479-828X.2008.00937.x.
3
Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor.巨噬细胞集落刺激因子增强卵巢癌的肿瘤发生和转移。
Neoplasia. 2009 Feb;11(2):136-44. doi: 10.1593/neo.81150.
4
Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer.HuR对乳腺癌中含非富AU元件的c-fms原癌基因表达的调控
Oncogene. 2009 Mar 5;28(9):1176-86. doi: 10.1038/onc.2008.469. Epub 2009 Jan 19.
5
Role of microRNAs in drug-resistant ovarian cancer cells.微小RNA在耐药性卵巢癌细胞中的作用。
Gynecol Oncol. 2008 Dec;111(3):478-86. doi: 10.1016/j.ygyno.2008.08.017. Epub 2008 Sep 26.
6
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.一项关于皮下注射A6用于上皮性卵巢癌一线化疗后出现无症状CA125进展的女性的临床活性和安全性的2期随机双盲安慰剂对照试验。
Gynecol Oncol. 2008 Oct;111(1):89-94. doi: 10.1016/j.ygyno.2008.06.028. Epub 2008 Aug 28.
7
The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is both regulated and controls colony-stimulating factor-1 messenger RNA stability in ovarian cancer.多功能蛋白甘油醛-3-磷酸脱氢酶在卵巢癌中既受到调控，又控制集落刺激因子-1信使核糖核酸的稳定性。
Mol Cancer Res. 2008 Aug;6(8):1375-84. doi: 10.1158/1541-7786.MCR-07-2170.
8
Circulating microRNAs as stable blood-based markers for cancer detection.循环微RNA作为基于血液的稳定癌症检测标志物
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. doi: 10.1073/pnas.0804549105. Epub 2008 Jul 28.
9
Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype.HuR介导的转录后基因调控促进了更具致瘤性的表型。
Oncogene. 2008 Oct 16;27(47):6151-63. doi: 10.1038/onc.2008.215. Epub 2008 Jul 21.
10
Cancer statistics, 2008.2008年癌症统计数据。
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
Zotero 插件